<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01975350</url>
  </required_header>
  <id_info>
    <org_study_id>201303119MINB</org_study_id>
    <nct_id>NCT01975350</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Pneumonia</brief_title>
  <official_title>Prospective Observation of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Tracheobronchitis/Pneumonia or Lower Respiratory Tract Colonization by Multidrug Resistant Gram-negative Bacteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There might be additional benefit on clinical outcomes from adjunctive colistimethate sodium&#xD;
      inhalation as therapy for multidrug resistant Gram-negative ventilator-associated pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Besides, early antibiotics intervention might be benefit for patients with&#xD;
      ventilator-associated tracheobronchitis or lower airway colonization with multidrug resistant&#xD;
      Gram-negative bacteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 1, 2013</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">February 4, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>clinical cure rate</measure>
    <time_frame>From date of starting colistimethate sodium to 28th days or til discharge from hospital, whichever came first, assessed up to 28 days</time_frame>
    <description>including clinical improvement and microbiological outcome(eradication of the pathogen as no growth of the pathogen in the final culture of specimens during the entire hospitalization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intensive care unit stay</measure>
    <time_frame>From date of starting colistimethate sodium to discharge date of intensive care unit, assessed up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>From date of starting colistimethate sodium to discharge date of hospital, assessed up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>From date of starting colistimethate sodium to 28th days or til death, whichever came first, assessed up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilator-associated pneumonia-related mortality</measure>
    <time_frame>Death that occurred during the colistimethate sodium treatment period when the signs of pneumonia remained and as death due to septic shock, assessed up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microbiologic eradication in colonization patients</measure>
    <time_frame>From date of starting colistimethate sodium to 28th days or til discharge from hospital, whichever came first, assessed up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilator-associated pneumonia rate</measure>
    <time_frame>From date of starting colistimethate sodium to discharge date of hospital, assessed up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">49</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Colistimethate sodium inhalation</arm_group_label>
    <description>Colistimethate sodium inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.&#xD;
Additional intravenous colistimethate sodium for patients with ventilator-associated pneumonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline inhalation</arm_group_label>
    <description>saline inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in medical intensive care unit with ventilator use&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age ≥ 20 years old&#xD;
&#xD;
          2. medical ICU patients with invasive ventilator use ≥ 48 hours&#xD;
&#xD;
          3. multidrug resistant Gram-negative bacteria obtained from lower respiratory tract&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. pregnancy&#xD;
&#xD;
          2. concurrent use of other antimicrobial agents active for isolated multidrug resistant&#xD;
             Gram-negative bacteria (as defined as resistant to carbapenem, fluoroquinolone, and&#xD;
             anti-pseudomonas beta-lactams), such as tigecycline, aminoglycosides, and sulbactam&#xD;
&#xD;
          3. patients who refuse to receive any inhaled therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang-Huei Sheng, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of Infection Control of National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2013</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colistimethate sodium inhalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

